先天免疫系统在肝细胞癌发生发展及治疗中的作用
The role of the innate immune system in the development and treatment of hepatocellular carcinoma.
作者信息
Roderburg Christoph, Wree Alexander, Demir Münevver, Schmelzle Moritz, Tacke Frank
机构信息
Department of Hepatology & Gastroenterology, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Campus Charité Mitte, Campus Virchow-Klinikum, Berlin Institute of Health, Augustenburger, Platz 1 13353, Berlin.
Department of Surgery, Charité, Universitätsmedizin Berlin,Humboldt-Universität zu Berlin, Campus Charité Mitte, Campus Virchow-Klinikum, Berlin Institute of Health, Augustenburger, Platz 1 13353, Berlin.
出版信息
Hepat Oncol. 2020 Jan 31;7(1):HEP17. doi: 10.2217/hep-2019-0007.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Most patients present with advanced or metastatic HCC at diagnosis and face a dismal prognosis. Tyrosine kinases are the gold standard treatment for this disease but yield limited survival benefits. Immune checkpoint inhibitors that augment adaptive immunity have been tested in HCC. Complex interactions between tumor cells, lymphocytes and the tumor environment determine the efficacy of such immunotherapies. Innate immune mechanisms - known drivers of liver disease progression in pre-HCC conditions such as fibrosis or cirrhosis - may either support or counteract tumor-related immune activation. In this review, we will highlight current concepts of the role of the innate immune system in hepatocarcinogenesis and discuss their relevance for translation into clinics.
肝细胞癌（HCC）是最常见的原发性肝癌。大多数患者在诊断时已出现晚期或转移性HCC，预后不佳。酪氨酸激酶是这种疾病的金标准治疗方法，但生存获益有限。增强适应性免疫的免疫检查点抑制剂已在HCC中进行了测试。肿瘤细胞、淋巴细胞和肿瘤环境之间的复杂相互作用决定了此类免疫疗法的疗效。先天性免疫机制——在纤维化或肝硬化等HCC前期肝病进展的已知驱动因素——可能支持或抵消肿瘤相关的免疫激活。在本综述中，我们将重点介绍先天性免疫系统在肝癌发生中的作用的当前概念，并讨论它们在转化为临床应用方面的相关性。
Zotero 插件